Pharm Exec8h
Local Pharmacies and Decentralized Clinical Trials: Q&A with Shelli Pavone
Why is there still a lack of diversity in clinical trials? Shelli Pavone: Unfortunately equity and healthcare have ...
Pharm Exec1d
Monitoring the Safety of WHISTLE-PF in IPF Across Diverse Populations
John Hood, CEO, Endeavor BioMedicines discusses a potential timeline on availability of ENV-101 for patients with IPF and further validation of the treatment's safety profile.
Pharm Exec4d
Biotech in the Empire State: Building a World-Class Bioscience Ecosystem in New York
Jennifer Hawks Bland, CEO of NewYorkBIO, shares her journey from litigation to biotech leadership, discusses fostering innovation in New York's thriving bioscience ecosystem, and outlines her vision ...
Pharm Exec4d
Zephound Expected to Surpass Wegovy in Weight Loss Market, New Report States
For the past two years, Ozempic and Wegovy have dominated the conversation when it comes to weight-loss medications (WLMs). The two medications, developed and distributed by Novo Nordisk, have made ...
Pharm Exec4d
Johnson & Johnson, Kaken Pharmaceutical Strike Licensing Agreement for the STAT6 Program That Targets Autoimmune, Allergic Diseases
Under terms of the deal, Johnson & Johnson will gain an exclusive license to the STAT6 program, with Kaken maintaining commercialization rights in Japan. Johnson & Johnson (J&J) announced that it has ...
Pharm Exec4d
Sanofi, SK Bioscience Launch Phase III Trial Program to Develop PCV21 for Pneumococcal Conjugate Vaccines
PCV21 is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter a Phase III clinical trial in infants and toddlers. Sanofi and SK Bioscience announced that they have ...
Pharm Exec4d
As Healthcare and Technology Intersect, Why Are Strong Communication Skills Crucial for Today and Tomorrow?
A Q&A with Harvard’s Laura Wegner, serial entrepreneur and Rhodes Scholar-elect. A. Wegner: While staying up to date on emerging technologies is valuable, improving communication skills is equally—if ...
Pharm Exec5d
FDA Regulations for CAR T-cell Therapy
The regulatory landscape for CAR T-cell therapies is constantly evolving with the FDA establishing their own guidelines needed for approval. Often, the approval can be long and difficult to obtain.
Pharm Exec5d
FDA Approves Subcutaneous Form of Bristol Myers Squibb's Opdivo Qvantig for Multiple Solid Tumor Indications
Approval was based on results from the Phase III CheckMate-67T trial, which demonstrated non-inferior pharmacokinetics compared to intravenous Opvido. The FDA has approved Bristol Myers Squibb’s (BMS) ...
Pharm Exec5d
The Future of Regulatory Processes in Cell and Gene Therapy
Regulatory agencies are open to changes within the review process which means the uptake of CAR T-cell therapy will change the landscape itself. This is especially true with large-scale ...
Pharm Exec5d
Final Thoughts
The panelists provide their closing thoughts on CAR T-cell therapies and what they look forward to as these therapies become popular beyond cancer, extending to autoimmune diseases as well. There is ...